Corgenix, BG combine in study partnership
This article was originally published in Clinica
Executive Summary
In vitro diagnostics company Corgenix Medical (Denver, Colorado) is set to make its AtherOx line of products available for studies conducted by life sciences firm BG Medicine, in a bid to help predict near-term risk of first myocardial infarction. The two firms have come together in a collaboration which will see Corgenix provide its IgG Anti-AtherOx, Anti-AtherOx IgM and AtherOx kits for BG’s studies of atherosclerosis and arterial lesions. Additionally, Corgenix said that it may use the data from the studies for its own regulatory and commercialisation purposes, in exchange for certain considerations. Financial terms of the partnership were not revealed.